Thalidomide: The Legacy of a Devastating Drug

Historical Tragedy

Thalidomide, marketed in the late 1950s as a safe sedative and anti-emetic for morning sickness, caused one of the worst drug disasters in history.

Catastrophic Effects

• Phocomelia: Severe limb reduction defects (flipper-like limbs) — hallmark malformation.
• Other defects: Amelia (absent limbs), micromelia, ear/eye malformations, cardiac defects, GI atresias, renal anomalies.
• Scale: ~10,000–20,000 affected children in 46 countries; ~40% mortality in first year.
• Critical period: Days 20–36 post-conception (limb bud development). Single dose could cause damage.

Regulatory Revolution

Before Thalidomide	After Thalidomide
Minimal pre-market testing	Mandatory phased clinical trials (Phase I–III)
No requirement for teratogenicity testing	Reproductive toxicity studies required
No formal adverse event reporting	Pharmacovigilance systems (FAERS, Yellow Card, EudraVigilance)
Manufacturer self-regulation	Strong regulatory agencies (FDA, EMA, PMDA) with approval authority
No informed consent standards	IRB/ethics committee oversight, informed consent mandatory

Key Legislative Milestones

• 1962 Kefauver-Harris Amendments (US): Proof of efficacy + safety; informed consent; FDA authority.
• 1965 Directive 65/65/EEC (Europe): Harmonized drug approval.
• 1975 Declaration of Helsinki revisions: Research ethics.

Thalidomide’s Return

Rediscovered for erythema nodosum leprosum (ENL) (1965) and later multiple myeloma (1999). Now approved with strict Risk Evaluation and Mitigation Strategies (REMS): pregnancy testing, contraception mandates, registry (S.T.E.P.S. program).

Enduring Lessons

• Animal models ≠ human teratogenicity.
• Post-marketing surveillance is essential.
• Regulatory independence from industry.
• Patient safety > speed to market.